Literature DB >> 22546752

γ-Glutamyl transferase: a marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome.

Diana Zaineff Banderas1, Jorge Escobedo, Evangelina Gonzalez, María Gabriela Liceaga, Jesus Cenobio Ramírez, María Guadalupe Castro.   

Abstract

OBJECTIVE: The incidence of metabolic syndrome has increased in Mexico and nonalcoholic fatty liver disease (NAFLD) is a common complication. The authors aimed to evaluate the role of hepatic enzymes as biomarkers for NAFLD in patients presenting metabolic syndrome.
METHODS: We studied 193 nondiabetic individuals with metabolic syndrome identified from a population-based cross-sectional survey. To identify NAFLD, real-time gray-scale abdominal ultrasound was performed, and the right, left, and caudate hepatic lobules were observed to assess the size, echogenicity, and borders of the liver. All individuals answered a questionnaire for risk factors, and anthropometric measures and blood pressure were obtained. The concentration of hepatic enzymes and insulin in blood was measured and the Homeostatic Model Assessment index was calculated.
RESULTS: A total of 160 individuals were identified as presenting NAFLD (82.9%). Body weight, BMI, and the waist-hip ratio increased as a direct result of the presence and severity of fatty liver. A similar situation was observed in the levels of triglyceride and hepatic enzymes aspartate aminotransferase and γ-glutamyltransferase (GGT), basal insulin level, and the Homeostatic Model Assessment index. In a multivariate model, the variables associated with the occurrence of NAFLD were sex, triglyceride and GGT levels, and obesity.
CONCLUSION: The main factors that predict the occurrence of NAFLD are levels of triglyceride and GGT in the blood, as well as obesity. The accumulation of fat in the liver, in addition to increased oxidation and oxidative stress at the hepatic level, may be the mechanisms through which these factors increase the risk of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22546752     DOI: 10.1097/MEG.0b013e328354044a

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  23 in total

1.  High mean platelet volume-to-platelet count ratio as a diagnostic maker for increased risk of liver function damage in pediatric patients with infectious mononucleosis in China.

Authors:  Xiucui Han; Pengfei Xu; Xiuzhi Duan; Yongxia Liu; Junfeng Zhang; Hui Xu
Journal:  Exp Ther Med       Date:  2019-10-15       Impact factor: 2.447

2.  Liver dysfunction in anti-melanoma differentiation-associated gene 5 antibody-positive patients with dermatomyositis.

Authors:  Takao Nagashima; Yasuyuki Kamata; Masahiro Iwamoto; Hitoaki Okazaki; Noriyoshi Fukushima; Seiji Minota
Journal:  Rheumatol Int       Date:  2019-02-21       Impact factor: 2.631

3.  Nonalcoholic fatty liver disease is associated with low HDL cholesterol and coronary angioplasty in patients with type 2 diabetes.

Authors:  Aleksandra Trojak; Małgorzata Waluś-Miarka; Ewa Woźniakiewicz; Maciej T Małecki; Barbara Idzior-Waluś
Journal:  Med Sci Monit       Date:  2013-12-16

4.  Pioglitazone, quercetin and hydroxy citric acid effect on hepatic biomarkers in Non Alcoholic Steatohepatitis.

Authors:  Krishna Mohan Surapaneni; Mallika Jainu
Journal:  Pharmacognosy Res       Date:  2014-04

5.  Comparison of serum ferritin and vitamin d in association with the severity of nonalcoholic Fatty liver disease in korean adults.

Authors:  Dong Wook Jeong; Hye Won Lee; Young Hye Cho; Dong Won Yi; Sang Yeoup Lee; Seok Man Son; Yang Ho Kang
Journal:  Endocrinol Metab (Seoul)       Date:  2014-12-29

6.  Serum gamma glutamyl transferase and alanine transaminase concentrations predict endothelial dysfunction in patients with non-alcoholic steatohepatitis.

Authors:  Huseyin Arinc; Bahadir Sarli; Ahmet Oguz Baktir; Hayrettin Saglam; Erkan Demirci; Yasemin Dogan; Serkan Kurtul; Hatice Karaman; Abdulsamet Erden; Ahmet Karaman
Journal:  Ups J Med Sci       Date:  2013-07-08       Impact factor: 2.384

7.  Fractionation of gamma-glutamyltransferase in patients with nonalcoholic fatty liver disease and alcoholic liver disease.

Authors:  Shigeo Sueyoshi; Setsu Sawai; Mamoru Satoh; Masanori Seimiya; Kazuyuki Sogawa; Atsushi Fukumura; Mikihiro Tsutsumi; Fumio Nomura
Journal:  World J Hepatol       Date:  2016-12-28

8.  The longitudinal effect of the aldehyde dehydrogenase 2*2 allele on the risk for nonalcoholic fatty liver disease.

Authors:  K Oniki; K Morita; T Watanabe; A Kajiwara; K Otake; K Nakagawa; Y Sasaki; Y Ogata; J Saruwatari
Journal:  Nutr Diabetes       Date:  2016-05-23       Impact factor: 5.097

9.  Metabolic Syndrome Augments the Risk of Early Neurological Deterioration in Acute Ischemic Stroke Patients Independent of Inflammatory Mediators: A Hospital-Based Prospective Study.

Authors:  Xiaohao Zhang; Zhiguang Sun; Caixia Ding; Yinyan Tang; Xuemei Jiang; Yi Xie; Chuanyou Li; Lankun Zhang; Dan Hu; Tingting Li; Gelin Xu; Lei Sheng
Journal:  Oxid Med Cell Longev       Date:  2016-03-29       Impact factor: 6.543

10.  Reduced Glutathione suppresses Oxidative Stress in Nonalcoholic Fatty Liver Disease.

Authors:  Makoto Irie; Tetsuro Sohda; Akira Anan; Atsushi Fukunaga; Kazuhide Takata; Takashi Tanaka; Keiji Yokoyama; Daisuke Morihara; Yasuaki Takeyama; Satoshi Shakado; Shotaro Sakisaka
Journal:  Euroasian J Hepatogastroenterol       Date:  2016-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.